Non-invasive electroceutical devices manufacturer BioElectronics has received 510(k) approval from the US Food and Drug Administration (FDA) for its drug-free ActiPatch medical device.

The FDA has granted marketing approval for the device as an over-the-counter adjunctive treatment of musculoskeletal pain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ActiPatch offers long-term chronic pain relief by deploying electromagnetic pulse therapy and works against back pain, knee pain, muscle & joint pain, arthritis, sciatica, fibromyalgia, strains and sprains.

BioElectronics president Kelly Whelan said: “The Company intends to capitalise on this new clearance by offering additional products to retail channel partners, in alignment with our 2020 strategy to prioritize the OEM (Original Equipment Manufacturer) aspects of our business.

“With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.”

BioElectronics sales and marketing vice president Keith Nalepka said: “The expanded clearance paves the way for new products to be marketed with approved medical claims for musculoskeletal pain, for instance, in the back, knee, hips, wrists, elbow and ankle.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2017, BioElectronics secured FDA approval for its ActiPatch, authorised for over-the-counter treatment of pain from knee osteoarthritis and plantar fasciitis.

As well as ActiPatch therapy, BioElectronics offers RecoveryRx Devices for chronic and post-operative wound care and Allay Menstrual Pain Therapy.